WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 15.60 | -1.37 | 1.51 | 1.13 |
| FCF Yield | 1.99% | 0.40% | -0.16% | -0.91% |
| EV / EBITDA | 9.54 | 19.00 | 32.75 | 74.13 |
| Quality | ||||
| ROIC | 7.96% | 7.66% | 8.84% | 7.37% |
| Gross Margin | 40.97% | 40.08% | 44.04% | 46.93% |
| Cash Conversion Ratio | 1.08 | 1.37 | 1.25 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.94% | 18.30% | 39.60% | 37.21% |
| Free Cash Flow Growth | 194.52% | 233.82% | 89.43% | 25.38% |
| Safety | ||||
| Net Debt / EBITDA | -0.52 | -0.93 | -0.32 | -1.04 |
| Interest Coverage | 31.56 | 28.08 | 67.44 | 81.35 |
| Efficiency | ||||
| Inventory Turnover | 7.25 | 5.78 | 3.75 | 3.24 |
| Cash Conversion Cycle | 138.74 | 165.86 | 186.81 | 187.59 |